Dolomite Bio launches an affordable microfluidic system for custom protocol development
Dolomite Bio scientist demonstrating pipetting into the Nadia Go
Dolomite Bio scientist demonstrating pipetting into the Nadia Go
Expanding precision medicine, ARTIS icono is designed to enable a wide procedure mix in a single interventional suite
These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales, and delivery to delight customers
The capital expansion program commenced in June 2022 and is expected to complete in 2024
The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved
The existing hospital premises has the scope to further scale up the bed capacity as and when required in the future with minimal Capex.
It is high time that India assumed a leadership role in healthcare.
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Subscribe To Our Newsletter & Stay Updated